MA28298A1 - Nouveaux pyrrolocarbazoles fondus - Google Patents

Nouveaux pyrrolocarbazoles fondus

Info

Publication number
MA28298A1
MA28298A1 MA29192A MA29192A MA28298A1 MA 28298 A1 MA28298 A1 MA 28298A1 MA 29192 A MA29192 A MA 29192A MA 29192 A MA29192 A MA 29192A MA 28298 A1 MA28298 A1 MA 28298A1
Authority
MA
Morocco
Prior art keywords
pyrrolocarbazoles
fondus
new
present
intermediates
Prior art date
Application number
MA29192A
Other languages
English (en)
Inventor
Nadine C Becknell
James L Diebold
Diane E Gingrich
Robert L Hudkins
Dandu R Reddy
Ming Tao
Theodore L Underiner
Allison L Zulli
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MA28298A1 publication Critical patent/MA28298A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention porte généralement sur les pyrrolocarbazoles fondus sélectionnés, y compris ses compositions pharmaceutiques et les méthodes de traitements des maladies ci-incluses. La présente invention est dirigée également aux intermédiaires et aux procesus pour la fabrication de ces pyrrolocarbazoles fondus.
MA29192A 2003-12-23 2006-07-17 Nouveaux pyrrolocarbazoles fondus MA28298A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53218203P 2003-12-23 2003-12-23
US11/017,947 US7169802B2 (en) 2003-12-23 2004-12-22 Fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
MA28298A1 true MA28298A1 (fr) 2006-11-01

Family

ID=34703676

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29192A MA28298A1 (fr) 2003-12-23 2006-07-17 Nouveaux pyrrolocarbazoles fondus

Country Status (30)

Country Link
US (4) US7169802B2 (fr)
EP (1) EP1704148B1 (fr)
JP (1) JP5006046B2 (fr)
KR (2) KR20120066057A (fr)
CN (1) CN1918162B (fr)
AR (1) AR047168A1 (fr)
AT (1) ATE500256T1 (fr)
AU (1) AU2004309394B2 (fr)
BR (1) BRPI0418113B8 (fr)
CA (1) CA2549627C (fr)
CR (1) CR8519A (fr)
CY (1) CY1111524T1 (fr)
DE (1) DE602004031672D1 (fr)
DK (1) DK1704148T3 (fr)
EA (1) EA012295B1 (fr)
HK (1) HK1096096A1 (fr)
HR (1) HRP20110373T1 (fr)
IL (1) IL176384A (fr)
IS (1) IS8519A (fr)
MA (1) MA28298A1 (fr)
MY (2) MY158159A (fr)
NO (2) NO336893B1 (fr)
NZ (1) NZ548099A (fr)
PL (1) PL1704148T3 (fr)
PT (1) PT1704148E (fr)
RS (1) RS51886B (fr)
SG (1) SG149045A1 (fr)
SI (1) SI1704148T1 (fr)
TW (1) TWI355385B (fr)
WO (1) WO2005063763A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP2064178A4 (fr) * 2006-09-08 2011-10-05 Merck Canada Inc Promédicaments d'inhibiteurs de la cathepsine s
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US9061009B2 (en) * 2007-06-08 2015-06-23 University Of Massachusetts Mixed lineage kinases and metabolic disorders
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
CN102307593B (zh) 2008-10-22 2016-04-13 弗·哈夫曼-拉罗切有限公司 轴突变性的调节
AU2009316600B2 (en) * 2008-11-19 2015-09-24 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (fr) * 2008-11-27 2010-06-02 Cephalon France Réduction régiosélective de pyrrolocarbazoles-5,7-diones fusionnées
ES2554623T3 (es) * 2008-12-30 2015-12-22 Arqule, Inc. Compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida
AU2009335016A1 (en) * 2008-12-30 2011-08-18 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
EP3011970A3 (fr) * 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation de la dégénérescence axonale
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
MX2012013304A (es) * 2010-05-18 2013-04-03 Cephalon France Metodo para purificar un derivado de pirrolocarbazol fusionado.
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
WO2014124454A1 (fr) 2013-02-11 2014-08-14 Katerina Gurova Utilisation du complexe 'facilite la transcription de la chromatine'(fact) en cancérologie
WO2015047982A2 (fr) * 2013-09-26 2015-04-02 Chdi Foundation, Inc. Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions
JP2017513933A (ja) 2014-04-06 2017-06-01 インクロン， リミテッド ライアビリティー カンパニー クラキシンとの併用療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
PL187205B1 (pl) 1996-08-22 2004-06-30 Bristol Myers Squibb Co Cytotoksyczne aminocukrowe i pokrewne cukrowe pochodne indolopirolokarbazoli
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
WO2002028861A2 (fr) 2000-09-29 2002-04-11 Eli Lilly And Company Procedes et composes pour le traitement de maladies proliferantes
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
WO2005063763A1 (fr) 2005-07-14
NZ548099A (en) 2010-05-28
CA2549627A1 (fr) 2005-07-14
DE602004031672D1 (de) 2011-04-14
US8044064B2 (en) 2011-10-25
US20060247294A1 (en) 2006-11-02
IL176384A (en) 2015-05-31
MY158159A (en) 2016-09-15
CA2549627C (fr) 2012-12-11
US7671064B2 (en) 2010-03-02
IS8519A (is) 2006-06-22
EP1704148A1 (fr) 2006-09-27
BRPI0418113B8 (pt) 2021-05-25
RS51886B (en) 2012-02-29
CY1111524T1 (el) 2015-08-05
CN1918162B (zh) 2014-05-14
BRPI0418113A (pt) 2007-04-17
PT1704148E (pt) 2011-05-25
US7169802B2 (en) 2007-01-30
MY143373A (en) 2011-04-29
EA012295B1 (ru) 2009-08-28
CR8519A (es) 2007-06-06
SI1704148T1 (sl) 2011-06-30
EP1704148B1 (fr) 2011-03-02
AU2004309394B2 (en) 2011-04-28
EA200601217A1 (ru) 2006-12-29
CN1918162A (zh) 2007-02-21
HK1096096A1 (en) 2007-05-25
JP5006046B2 (ja) 2012-08-22
JP2007516293A (ja) 2007-06-21
NO20063196L (no) 2006-09-20
DK1704148T3 (da) 2011-06-14
ATE500256T1 (de) 2011-03-15
US20120004253A1 (en) 2012-01-05
US20100152196A1 (en) 2010-06-17
NO20151245A1 (no) 2015-09-23
KR20060127069A (ko) 2006-12-11
US8383813B2 (en) 2013-02-26
AR047168A1 (es) 2006-01-11
HRP20110373T1 (hr) 2011-06-30
BRPI0418113B1 (pt) 2020-04-14
KR20120066057A (ko) 2012-06-21
TW200530243A (en) 2005-09-16
TWI355385B (en) 2012-01-01
KR101179372B1 (ko) 2012-09-03
NO336893B1 (no) 2015-11-23
PL1704148T3 (pl) 2011-07-29
IL176384A0 (en) 2006-10-05
AU2004309394A1 (en) 2005-07-14
US20050143442A1 (en) 2005-06-30
SG149045A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
MA28298A1 (fr) Nouveaux pyrrolocarbazoles fondus
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
MXPA03010909A (es) Derivados de epotilona.
CY1122238T1 (el) Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
DE60239931D1 (de) Kombinationstherapie
SG149042A1 (en) Novel fused pyrrolocarbazoles
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
UA84726C2 (ru) Производные простагландинов, способ их получения, фармацевтическая композиция (варианты) и способ лечения глаукомы или гипертензии глаза
NO20034056D0 (no) Proliferative sykdommer
MA29088B1 (fr) Composes d'indazole-carboxamide.
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
PL370435A1 (en) Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
EA200000322A1 (ru) Способ синтеза производных хинолина
CY1106409T1 (el) Παραγωγα κινολινης
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
NO20024503L (no) FremgangsmÕte for tilveiebringelse av startkulturer med en konsistent kvalitet
ATE353693T1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
UA87829C2 (en) Fused pyrrolocarbazoles
DE60006125D1 (de) Herstellung von 2-(2-arylmorpholin-2-yl)ethanolderivaten und zwischenprodukte